Statin/Ezetimbe Combination Therapy: Emerging Evidence
Statin/Ezetimbe Combination Therapy: Emerging Evidence
Statin/Ezetimbe Combination Therapy: Emerging Evidence
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
First ESC/EAS guidelines for dyslipidemia<br />
- EAS 2011 Gothenburg, Sweden<br />
ESC/EAS<br />
2011<br />
Guidelines<br />
Bile acid sequestrants or nicotinic acid, or a cholesterol absorportion inhibitor,<br />
either alone or in combination with bile acid sequestrants or nicotinic acid,<br />
can be considered in patients who do not tolerate statins.<br />
<strong>Statin</strong> combination therapy with either a cholesterol absorption<br />
inhibitor, bile acid sequestrant or nicotinic acid may be considered if<br />
the target level is not reached.<br />
Chronic kidney disease (CKD) is regarded as a coronary artery<br />
disease equivalent with LDL cholesterol as the primary target for<br />
treatment. <strong>Statin</strong>s are the first line treatment and also have protective effects<br />
on the rate of kidney function loss and on proteinuria. Patients with<br />
moderate to severe CKD should be considered as very high risk and<br />
clinicians should therefore aim to achieve a LDL cholesterol target of<br />
Change language